Carmine N. Stengone, CEO and President at Contineum Therapeutics, sold CTNM on Aug 3, 2026
Data as of Oct 27
▼ SELL$40K2,500 shares at $16.01Carmine N. Stengone CEO and PresidentCTNM Contineum Therapeutics, Inc.
- Traded
- Aug 3, 2026
- Disclosed
- Aug 3, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
CTNM since disclosure
−43.6%
after the sale
Similar stocks (XLV) since disclosure
+10.4%
XLV — its sector index fund
Change in closing price from Aug 3, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.